Vigil Neuroscience, Inc. (VIGL) Financial Analysis & Valuation | Quarter Chart
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is des... more
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifyi... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $375.71M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Ivana Magovcevic-Liebisch |
| IPO Date | 2022-01-07 | CAGR | — |
| Employees | 69 | Website | www.vigilneuro.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
VIGL chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $349.80M | P/E | -3.83 | Forward P/E | — | PEG | — |
| P/S | 831.21 | P/B | 9.29 | P/CF | -6.13 | P/FCF | -5.98 |
| Sales | $452,000 | Sales 1Y | -76.63% | Sales 3Y | — | Sales 5Y | — |
| EPS | $-2.1 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | — | EPS QoQ | 14.29% | Sales QoQ Avg | — | EPS QoQ Avg | 2.98% |
| Gross Margin | 22.57% | Operating Margin | -16830.53% | Profit Margin | -16129.87% | ROCE | -144.66% |
| ROA | -84% | ROE | -123% | Altman Z Score | -3.93 | Piotroski Score | 1 |
| Current Ratio | 2.06 | Quick Ratio | 2.06 | Cash Ratio | 1.21 | Op. CF Ratio | -0.6 |
| Debt/Equity | 0.3 | Debt/Assets | 0.14 | Lt Debt/Equity | 0.27 | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.01 | Receivables Turnover | 0.81 |
| Enterprise Value | $349.80M | P/E Ratio | -3.83 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 831.21 | P/B Ratio | 9.29 |
| P/CF Ratio | -6.13 | P/FCF Ratio | -5.98 |
| EPS | $-2.1 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -76.63% | Gross Margin | 22.57% |
| Operating Margin | -16830.53% | Profit Margin | -16129.87% |
| ROE | -123% | ROA | -84% |
| ROCE | -144.66% | Current Ratio | 2.06 |
| Quick Ratio | 2.06 | Cash Ratio | 1.21 |
| Debt/Equity | 0.3 | Interest Coverage | — |
| Altman Z Score | -3.93 | Piotroski Score | 1 |
Vigil Neuroscience, Inc. (VIGL) valuation & financials
Vigil Neuroscience, Inc. (VIGL) has a market capitalization of $375.71M and trades at a price-to-earnings ratio of -3.8. It operates in the Healthcare sector (Biotechnology).
Vigil Neuroscience, Inc.'s revenue grew -76.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)